Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Buy” by Brokerages
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued ratings on the stock in the […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued ratings on the stock in the […]